March 03, 2005 10:05 ET

Effective Measures Needed to Reduce Tobacco's Deadly Toll; Nymox -NASDAQ: NYMX- Products Provide Cost-Effective Tools for the Measurement of Tobacco Use and Exposure




MARCH 3, 2005 - 10:05 ET

Effective Measures Needed to Reduce Tobacco's Deadly
Toll; Nymox -NASDAQ: NYMX- Products Provide
Cost-Effective Tools for the Measurement of Tobacco
Use and Exposure

MAYWOOD, N.J.--(CCNMatthews - Mar 3, 2005) -

The coming into force of a global treaty aimed at reducing the death
toll worldwide from tobacco use and exposure to second hand smoke
highlights the need for effective tobacco control measures, according to
Brian Doyle, Global Sales Manager for Nymox Pharmaceutical Corporation
(NASDAQ: NYMX). The treaty, known as the WHO Framework Convention on
Tobacco Control, came into effect February 27 in the 57 countries which
have ratified it to date. The treaty requires the countries to adopt and
implement measures to reduce exposure to second hand smoke, to diagnose
tobacco dependence and to promote tobacco use cessation. The WHO
estimates that tobacco use and exposure currently kills 4.9 million
people a year worldwide with the annual death toll rising to an
estimated 10 million by 2020.

Nymox offers innovative, cost-effective products, including
TobacAlert™, for the detection and measurement of second hand smoke
exposure and tobacco product use. TobacAlert™ is Nymox's
revolutionary new product that allows concerned individuals to determine
second hand smoke exposure or tobacco use by measuring the level of
cotinine, a metabolite of nicotine, in urine. TobacAlert™ is a quick,
accurate and easy to use test that can be done almost anywhere,
including at home, the workplace or school and that requires no
instruments to use.

A new study published in the online edition of the British Medical
Journal illustrates the impact second hand smoke exposure has on public
health and the need for such measures. The study estimates that exposure
to second hand smoke at work is responsible for the deaths of more than
two employed people per working day (617 deaths per year), including 54
deaths in the hospitality industry, in the United Kingdom alone (BMJ
(March 2, 2005) BMJ, doi:10.1136/bmj.38370.496632.8F). An estimated
10,700 deaths a year in the U.K. were caused by second hand smoke
exposure at home. The authors conclude that smoke free policies in the
workplace and reductions in the general prevalence of active smoking
would lead to substantial reductions in these avoidable deaths.

TobacAlert™ is available at the approximately 5,400 CVS/pharmacy®
stores across the U.S. as well as online at www.cvs.com.

TobacAlert™ uses patented technology to provide a semi-quantitative
measure of cotinine, a byproduct of the body's metabolism of nicotine.
Cotinine is widely accepted and commonly used in medical research and
public health studies to determine the extent of tobacco product
exposure. TobacAlert™ is intended only to assess an individual's
level of tobacco product exposure and not for any medical treatment
purposes. More information about TobacAlert™ is available at

More information about Nymox is available at www.nymox.com, email:
info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as
defined in the United States Private Securities Litigation Reform Act of
1995 that involve a number of risks and uncertainties. There can be no
assurance that such statements will prove to be accurate and the actual
results and future events could differ materially from management's
current expectations. Such factors are detailed from time to time in
Nymox's filings with the United States Securities and Exchange
Commission and other regulatory authorities.


Contact Information

    Nymox Pharmaceutical Corporation
    Roy Wolvin, 1-800-93NYMOX